Initial Experience With Nifekalant Hydrochloride (MS-551), A Novel Class III Antiarrhythmic Agent, in Patients With Acute Extensive Infarction and Severe Ventricular Dysfunction

  • Takenaka Kotoe
    Division of Cardiology, Department of Medicine, National Cardiovascular Center
  • Yasuda Satoshi
    Division of Cardiology, Department of Medicine, National Cardiovascular Center
  • Miyazaki Shunichi
    Division of Cardiology, Department of Medicine, National Cardiovascular Center
  • Kurita Takashi
    Division of Cardiology, Department of Medicine, National Cardiovascular Center
  • Sutani Yasuo
    Division of Cardiology, Department of Medicine, National Cardiovascular Center
  • Morii Isao
    Division of Cardiology, Department of Medicine, National Cardiovascular Center
  • Daikoku Satoshi
    Division of Cardiology, Department of Medicine, National Cardiovascular Center
  • Kamakura Shiro
    Division of Cardiology, Department of Medicine, National Cardiovascular Center
  • Nonogi Hiroshi
    Division of Cardiology, Department of Medicine, National Cardiovascular Center

この論文をさがす

抄録

Nifekalant hydrocholoride, a novel class III antiarrhythmic agent, was used as the treatment in 4 patients with extensive anterior infarction and severe ventricular dysfunction. The malignant ventricular tachyarrhythmia was effectively suppressed at a relatively low dose, without compromising the hemodynamics, indicating that this potent K+ channel blocker has therapeutic potential for acute myocardial infarction. (Jpn Circ J 2001; 65: 60 - 62)

収録刊行物

被引用文献 (22)*注記

もっと見る

参考文献 (16)*注記

もっと見る

詳細情報

問題の指摘

ページトップへ